186 related articles for article (PubMed ID: 15329162)
1. Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery.
Turanlahti M; Boldt T; Palkama T; Antila S; Lehtonen L; Pesonen E
Pediatr Crit Care Med; 2004 Sep; 5(5):457-62. PubMed ID: 15329162
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure.
Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
Int J Clin Pharmacol Ther; 2002 Oct; 40(10):465-71. PubMed ID: 12395979
[TBL] [Abstract][Full Text] [Related]
4. The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure.
Harjola VP; Oikarinen L; Toivonen L; Jurkko R; Puttonen J; Sarapohja T; Sundberg S; Nieminen MS
Int J Clin Pharmacol Ther; 2008 Aug; 46(8):389-99. PubMed ID: 18793580
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic preoperative levosimendan administration in heart failure patients undergoing elective non-cardiac surgery: a preliminary report.
Katsaragakis S; Kapralou A; Drimousis P; Markogiannakis H; Larentzakis A; Kofinas G; Misthos P; Filis K; Theodorou D
Hellenic J Cardiol; 2009; 50(3):185-92. PubMed ID: 19465359
[TBL] [Abstract][Full Text] [Related]
6. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.
Slawsky MT; Colucci WS; Gottlieb SS; Greenberg BH; Haeusslein E; Hare J; Hutchins S; Leier CV; LeJemtel TH; Loh E; Nicklas J; Ogilby D; Singh BN; Smith W
Circulation; 2000 Oct; 102(18):2222-7. PubMed ID: 11056096
[TBL] [Abstract][Full Text] [Related]
7. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.
Nieminen MS; Akkila J; Hasenfuss G; Kleber FX; Lehtonen LA; Mitrovic V; Nyquist O; Remme WJ
J Am Coll Cardiol; 2000 Nov; 36(6):1903-12. PubMed ID: 11092663
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan.
Antila S; Kivikko M; Lehtonen L; Eha J; Heikkilä A; Pohjanjousi P; Pentikäinen PJ
Br J Clin Pharmacol; 2004 Apr; 57(4):412-5. PubMed ID: 15025738
[TBL] [Abstract][Full Text] [Related]
9. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals.
Sundberg S; Antila S; Scheinin H; Häyhä M; Virtanen M; Lehtonen L
Int J Clin Pharmacol Ther; 1998 Dec; 36(12):629-35. PubMed ID: 9876999
[TBL] [Abstract][Full Text] [Related]
10. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril.
Antila S; Eha J; Heinpalu M; Lehtonen L; Loogna I; Mesikepp A; Planken U; Sandell EP
Eur J Clin Pharmacol; 1996; 49(6):451-8. PubMed ID: 8706769
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers.
Lilleberg J; Antila S; Karlsson M; Nieminen MS; Pentkäinen PJ
Clin Pharmacol Ther; 1994 Nov; 56(5):554-63. PubMed ID: 7955820
[TBL] [Abstract][Full Text] [Related]
12. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.
Puttonen J; Kantele S; Kivikko M; Häkkinen S; Harjola VP; Koskinen P; Pentikäinen PJ
Clin Pharmacokinet; 2007; 46(3):235-46. PubMed ID: 17328582
[TBL] [Abstract][Full Text] [Related]
13. The Hemodynamic Effects and Safety of Repetitive Levosimendan Infusions on Children With Dilated Cardiomyopathy.
Suominen P; Mattila N; Nyblom O; Rautiainen P; Turanlahti M; Rahkonen O
World J Pediatr Congenit Heart Surg; 2017 Jan; 8(1):25-31. PubMed ID: 28033083
[TBL] [Abstract][Full Text] [Related]
14. Levosimendan infusion in newborns after corrective surgery for congenital heart disease: randomized controlled trial.
Ricci Z; Garisto C; Favia I; Vitale V; Di Chiara L; Cogo PE
Intensive Care Med; 2012 Jul; 38(7):1198-204. PubMed ID: 22527079
[TBL] [Abstract][Full Text] [Related]
15. Haemodynamic dose-efficacy of levosimendan in healthy volunteers.
Lilleberg J; Sundberg S; Häyhä M; Akkila J; Nieminen MS
Eur J Clin Pharmacol; 1994; 47(3):267-74. PubMed ID: 7867680
[TBL] [Abstract][Full Text] [Related]
16. The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan.
Antila S; Honkanen T; Lehtonen L; Neuvonen PJ
Int J Clin Pharmacol Ther; 1998 Aug; 36(8):446-9. PubMed ID: 9726699
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines.
Delle Karth G; Buberl A; Geppert A; Neunteufl T; Huelsmann M; Kopp C; Nikfardjam M; Berger R; Heinz G
Acta Anaesthesiol Scand; 2003 Nov; 47(10):1251-6. PubMed ID: 14616323
[TBL] [Abstract][Full Text] [Related]
18. Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study.
Bocchi EA; Vilas-Boas F; Moreira Mda C; Barretto AC; Lage S; Albuquerque D; Baima J; Rassi S; Ribeiro JP; ;
Arq Bras Cardiol; 2008 Mar; 90(3):182-90. PubMed ID: 18392398
[TBL] [Abstract][Full Text] [Related]
19. Effect of Preoperative Infusion of Levosimendan on Biomarkers of Myocardial Injury and Haemodynamics After Paediatric Cardiac Surgery: A Randomised Controlled Trial.
Abril-Molina A; Gómez-Luque JM; Perin F; Esteban-Molina M; Ferreiro-Marzal A; Fernandez-Guerrero C; Ocete-Hita E
Drugs R D; 2021 Mar; 21(1):79-89. PubMed ID: 33367965
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic use of levosimendan in pediatric patients undergoing cardiac surgery: a prospective randomized controlled trial.
Wang A; Cui C; Fan Y; Zi J; Zhang J; Wang G; Wang F; Wang J; Tan Q
Crit Care; 2019 Dec; 23(1):428. PubMed ID: 31888711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
